Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial
- C.J. Bailey*
- , E.C. Morales Villegas
- , V. Woo
- , W. Tang
- , A. Ptaszynska
- , J.F. List
*Corresponding author for this work
- Aguascalientes Cardiometabolic Research Center
- University of Manitoba
- Bristol-Myers Squibb, Princeton
- Bristol-Myers Squibb
Research output: Contribution to journal › Article › peer-review
137
Link opens in a new tab
Citations
(SciVal)